Hematopoietic stem cell transplantation in the treatment of peripheral T-cell lymphomas.
Peripheral T-cell lymphomas (PTCL) are a rare group of heterogeneous lymphoproliferative disorders with their origin in the post-thymic T cells. Most PTCL have a relatively poor outcome, with a 5-year overall survival of less than 30%. Anaplastic large cell lymphoma (ALCL) has a better prognosis compared with other subtypes of PTCL. As with aggressive B-cell non-Hodgkin's lymphoma, high-dose chemotherapy followed by autologous stem cell transplantation should be offered to patients with PTCL in their first relapse. Patients with poor-risk features (alk-negative ALCL, histologic subtypes other than ALCL, and high International Prognostic Index score at presentation) may be candidates for autologous stem cell transplantation as first-line therapy. Initial results of allogeneic stem cell transplantation, both with standard and nonmyeloablative conditioning, look promising. Randomized, multi-institutional clinical trials are needed to optimally define the role of stem cell transplantation in PTCL.
Majhail
Navneet S
NS
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Mayo Mail Code 286, 420 Delaware St. SE, Minneapolis, MN 55455, USA.
Burns
Linda J
LJ
D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016130:Immunophenotyping; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis / Q000601:surgery*; D011379:Prognosis; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous